CytoSorbents Corp (NAS:CTSO)
$ 0.9 -0.0333 (-3.57%) Market Cap: 48.88 Mil Enterprise Value: 57.88 Mil PE Ratio: 0 PB Ratio: 2.58 GF Score: 62/100

Cytosorbents Corp at UBS Global Healthcare Conference Transcript

May 23, 2022 / 01:15PM GMT
Release Date Price: $2 (-5.21%)
Benjamin Nicholas Bible

Hi, everyone. Good morning. Welcome to the 2022 UBS Global Healthcare Conference. My name is Ben Bible, and really appreciate your time this morning.

With us today to walk through the story is Phil Chan, CEO of CytoSorbents. Phil will take you through the story, and we'll do Q&A at the end. This is meant to be an interactive session. (Operator Instructions)

Phil, thank you very much for making the trip today. The floor is yours.

Phillip P. Chan
Cytosorbents Corporation - CEO & Director

Well, thank you very much, Ben. And thank you, and also UBS for this kind invitation to present here today. I'm excited to finally be in front of investors, not over Zoom, but actually in person, which is great.

Today, I'd like to tell you about CytoSorbents NASDAQ-traded medical device company working to help treat life-threatening conditions in the ICU and cardiac surgery with our CytoSorb blood purification technology.

I'm here today with my Chief Financial Officer, Kathy Bloch; and my Vice President of Investor

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot